Recent Updates
Recently added Catalysts
MRVI Negative Sentiment Score: 25/100

Maravai LifeSciences Holdings, Inc. Shareholder Notice: Robbins LLP Reminds Investors of the Class Action Lawsuit Against MRVI

Key Takeaway: Robbins LLP has announced a class action lawsuit against Maravai LifeSciences Holdings, Inc. for allegations of improper revenue recognition and lack of adequate internal controls over financial reporting. The lawsuit affects shareholders who purchased MRVI securities between August 7, 2024, and February 24, 2025. Following the disclosure of these issues, the company's stock experienced a significant drop of over 21%. Shareholders have until May 5, 2025, to file papers for participation in the class action.

Market Sentiment Analysis

CONCERNS & RISKS

  • Maravai is facing a class action lawsuit for allegedly recording unearned revenues.
  • The company acknowledged a material weakness in internal revenue recognition controls.
  • Stock price fell over 21% to $3.14 per share following the revelation of the financial discrepancies.

Full Press Release Details

SAN DIEGO, March 08, 2025 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of persons and entities that purchased or otherwise acquired Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) securities between August 7, 2024 and February 24, 2025. Maravai is a life sciences company that provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide.
For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003.
The Allegations: Robbins LLP is Investigating Allegations that Maravai LifeSciences Holdings, Inc. (MRVI) Intentionally Recorded Unearned Revenues
According to the complaint, during the class period, defendants failed to disclose to investors that: (1) Maravai lacked adequate internal controls over financial reporting related to revenue recognition; (2) as a result, the Company inaccurately recognized revenue on certain transactions during fiscal 2024; (3) its goodwill was overstated; and (4) that, as a result of the foregoing, defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
On February 25, 2025, Maravai revealed it identified an error in revenue recognition and "a material weakness in its internal controls over revenue recognition. On this news, the price of the Company's stock fell over 21% to close at $3.14 per share on February 25, 2025.
What Now: You may be eligible to participate in the class action against Maravai LifeSciences Holdings, Inc. Shareholders who want to serve as lead plaintiff for the class must file their papers with the court by May 5, 2025. A lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information, click here.
All representation is on a contingency fee basis. Shareholders pay no fees or expenses.
About Robbins LLP: A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002.
Attorney Advertising. Past results do not guarantee a similar outcome.
Maravai LifeSciences Holdings, Inc.
Maravai LifeSciences Holdings. Inc. sued by shareholders for recording unearned revenues

Frequently Asked Questions

What is the class action against Maravai LifeSciences about?

The class action claims Maravai LifeSciences inaccurately recognized revenue and lacked proper financial controls.

Who can participate in the class action against Maravai?

Shareholders who purchased Maravai securities between August 7, 2024, and February 24, 2025, may participate.

What happened to Maravai's stock on February 25, 2025?

Maravai's stock price dropped over 21% to $3.14 after revealing revenue recognition errors.

When do lead plaintiff papers need to be filed?

Papers must be filed by May 5, 2025, to serve as lead plaintiff in the class action.

Is there a cost to participate in the class action?

No, all representation is on a contingency fee basis, meaning no upfront costs for shareholders.

Last updated: Mar 8, 2025